Yorkshire biotech business Aptamer Group is toasting a 40% rise in revenues, boosted by repeat business with multiple top 20 pharmaceutical companies.

The York company manufactures synthetic binders which are used in medicine, diagnostic tests, and research tools, and entered AIM four years ago, to capitalise on the potential of its optimer binder technology.

Now the firm has released full year results for the company, covering the year ended June 30 2025, in which revenues rose 40% to £1.2m, while its Ebitda losses narrowed from £2.8m to £2.2m. Its cash balance at the year end was £1.1m, up from £900,000 a year earlier.

Over the year, bosses said Aptamer had demonstrated significant progress, "both in terms of technical and financial development", with notable highlights including securing a significant contract with a top five pharmaceutical company for the discovery of Optimer binders and the development of an immunoassay.

It successfully completed fundraising for £1.8m in July 2025, further strengthening the group's financial position. Meanwhile, in the first quarter it secured £675,000 in new contracts, and was supported by a robust £3.4m sales pipeline.

Arron Tolley, chief executive officer of Aptamer Group, said: "This has been a year of significant strategic progress for Aptamer as we continued to expand the breadth and commercial reach of our Optimer platform. With a 40% increase in revenue and a growing base of repeat business from leading pharmaceutical partners.

"Our technology is gaining strong traction across life sciences and adjacent markets. We have more than doubled Aptamer's portfolio of licensable Optimer assets from four to eleven, secured royalty-bearing agreements with Neuro-Bio and the University of Glasgow, and a global life science conglomerate.

"Additionally, we are in late-stage licensing negotiations for our enzyme-modulating assets, with two separate partners, which are expected to sign in the coming months. The expansion of our Unilever partnership, now including a second Optimer development programme, underlines the commercial strength and versatility of our platform technology.

"Looking ahead, the successful £1.8m fundraising completed after year-end provides the resources to accelerate our growth strategy, strengthen in-house manufacturing, and advance high-value Optimer programmes. With an expanding pipeline, deepening commercial relationships, and a robust financial position, we are well-placed to deliver long-term value for our shareholders."